Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEVENAZA
2025-521634-29-00Phase 3Authorised
- Sponsor
- Gustave Roussy
- Start
- Mar 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of venetoclax and azacitidine in acute myeloid leukemia (AML) (2 arms), sponsored by Gustave Roussy. Primary endpoint: CR/CRi rate. Planned start Mar 2026; status: authorised.
02
Drugs
venetoclaxazacitidine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2025-521634-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521634-29-00.